SESSIONS WILL BE DIVIDED INTO 3 TRACKS PRIOR TO THE EVENT. DELEGATES WILL BE FREE TO CHOOSE FROM TRACK 1, 2 or 3 AT ANY TIME.
THE DAY WILL START WITH NETWORKING AT 08:00 AND CONCLUDE WITH A NETWORKING SESSION FINISHING AT 17:00.
08:00 – 08:55
How does a CDMO manage the natural uncertainties of an early development HPAPI compound?
High potent active pharmaceutical ingredients (HPAPI) are effective at much smaller dosage levels than traditional APIs, but their potent characteristics present specific handling challenges. Meet the team from SK pharmteco to understand their perspective.
Pre-registration is required. Please email Jo Stickings to receive your invitation.
08:00 – 08:55
Networking
08:55 – 09:00
Welcome
TREVOR JONES CBE | Director | Arix Bioscience plc and e-Therapeutics plc
Recession, a global pandemic, Brexit – it’s fair to say the events of the past decade have shaped the pharma industry landscape. How has it responded to these challenges and how can it make the most of future opportunities? How will innovation in product quality, manufacturing and working practises drive future productivity?
Sponsored By: Medicines Manufacturing Innovation Centre, CPI
TREATMENT
With the ever increasing focus on personalised medicines, what strategies are we putting in place to ensure new drugs hit the 5Rs? Are we maximising clinical data? What does this mean for rare diseases?
Sponsored By: Medicines Manufacturing Innovation Centre, CPI
TECHNOLOGY
How are tech giants and pharma companies collaborating to drive innovation in healthcare? What are the large pharma companies really looking for when it comes to new technologies, and at what stage will they pay for them? Is pharma manufacturing making the most of the digital revolution? Will COVID-19 change all of this?
Sponsored By: Medicines Manufacturing Innovation Centre, CPI
TRENDS
Recession, a global pandemic, Brexit – it’s fair to say the events of the past decade have shaped the pharma industry landscape. How has it responded to these challenges and how can it make the most of future opportunities? How will innovation in product quality, manufacturing and working practises drive future productivity?
Session 2
11:00 – 11:50
Partnership for innovation: How medicines will be made in future
Sponsored By: Medicines Manufacturing Innovation Centre, CPI
08:00 – 09:00
Networking
08:55 – 09:15
Welcome and Opening Remarks
TRENDS
Recession, a global pandemic, Brexit – it’s fair to say the events of the past decade have shaped the pharma industry landscape. How has it responded to these challenges and how can it make the most of future opportunities? How will innovation in product quality, manufacturing and working practises drive future productivity?
Sponsored By: Medicines Manufacturing Innovation Centre, CPI
TREATMENT
With the ever increasing focus on personalised medicines, what strategies are we putting in place to ensure new drugs hit the 5Rs? Are we maximising clinical data? What does this mean for rare diseases?
Sponsored By: Medicines Manufacturing Innovation Centre, CPI
TECHNOLOGY
How are tech giants and pharma companies collaborating to drive innovation in healthcare? What are the large pharma companies really looking for when it comes to new technologies, and at what stage will they pay for them? Is pharma manufacturing making the most of the digital revolution? Will COVID-19 change all of this?
Sponsored By: Medicines Manufacturing Innovation Centre, CPI
TRENDS
Recession, a global pandemic, Brexit – it’s fair to say the events of the past decade have shaped the pharma industry landscape. How has it responded to these challenges and how can it make the most of future opportunities? How will innovation in product quality, manufacturing and working practises drive future productivity?
11:00 – 11:50 Session 3:
Partnership for innovation: how medicines will be made in future
The pharma and lifesciences ecosystem was already facing significant opportunities and disruption from technology advances, pricing pressure, digital and new entrants. In a Covid-19 world and with Brexit uncertainty the level of disruption has only been amplified. This panel will explore the disruptive themes and key success factors for companies to navigate our changing environment.
FACILITATED BY
JO PISANI | Strategic Advisor, Non Executive Director and Charity Trustee
PANELLISTS INCLUDE
JOHN DAWSON | Chief Executive Officer | Oxford Biomedica RICHARD TORBETT | Chief Executive Officer | ABPI BRIAN HENRY | Vice President, Global Head of Drug Product Design | Pfizer Worldwide Research and Development GLENN CROCKER | Head of Life Sciences, JLL & Chairman, BioCity Group | JLL & BioCity Group NICOLE MATHER | Executive Partner, Life Sciences Lead | IBM Services
With the end of the transition period in sight, will Brexit bring a fanfare or a frenzy to Pharma?
FACILITATED BY
CLAIRE THOMPSON | Chief Executive Officer | Agility Life Sciences
PANELLISTS INCLUDE
SCOTT JOHNSTONE | Chief Executive Officer | Scottish Lifesciences Association HUGO FRY | Managing Director & Vice President | Sanofi UK & ABPI TAMSIN BERRY | Director | PHP JON NEAL | Managing Director | Takeda UK & Ireland TASMINA GORAYA | Partner, IP and Life Sciences Regulatory | Taylor Wessing
Taking stock: Impact on supply chains in a post Covid world
The COVID 19 virus pandemic has rocked the world to its core. There are likely to be many and far-reaching consequences of this on the Pharmaceutical industry. One aspect that will come under scrutiny is in the area of risk management and continuity of Pharmaceutical supply chains. What have we learned that will shape supply chains of the future? What innovations have been accelerated to address the challenges? Will we see radical changes in the factors pharma companies consider when making outsourcing decisions? Will they recalculate the balance between working capital and inventory management? Will large companies consider a slowing or even reversal in the trend to outsource API/DP manufacture, with greater investment in internal assets?
FACILITATED BY
ALEX ROBERTSON | Senior Director, Global Clinical Supply Chain | AstraZeneca
PANELLISTS INCLUDE
JIM FOX | VP & Site Director, PSC Ware Site | GlaxoSmithKline PETER LYFORD | Business Development Director | Porton Pharma Solutions MARC CREUS | Head of Business Development | Juvabis Therapeutics SEAMUS RYAN | Head of Supply Chain and Project Management | SK Biotek Ireland
In discussion with Andy Plump President, Research & Development, Takeda Pharmaceutical Company. Topics will include the international collaborative initiatives on COVID-19 R&D, the status of progress on vaccines and therapeutic agents, data sharing and possible new partnerships for preparedness for the next pandemics.
Accessing and stratifying patient groups for clinical trials and maximising clinical data. Engaging patients to become drivers of their own healthcare.
FACILITATED BY
EMMA PALMER FOSTER | Healthcare Consultant, Corporate & Financial Strategy | IR | Communications | EJ Palmer Consulting
What are we doing differently now that’s better than before? What do we foresee might be future benefits of new ways of working?
FACILITATED BY
TINA FLATAU | Chief Executive Officer | Biopharma Projects
PANELLISTS INCLUDE
FLIC GABBAY | Managing Partner | tranScrip DAVID HAWKINS | Founder and Chief Executive Officer | Remedium Capital HELEN BARKER | Head of Pharmaceutical Development | Reneo Pharma SEAN BREEN | Head Public Private Partnerships and Science Policy | Takeda GRAHAM WYLIE | Chief Executive Officer | MRN
Respiratory diseases remain a key target for pharma companies. Are we maximising our assets and this as a drug delivery route?
FACILITATED BY
MARK DUMAN | Chief Patient Officer | MD Healthcare Consultants
PANELLISTS INCLUDE
MARK MILTON-EDWARDS | Head of Health Solutions – Digital Health | TEVA Pharmaceuticals GERALDINE VENTHOYE | Chief Scientific Officer & Executive Vice President – Product Development | Vectura DOMINIC BRITTAIN | Senior Global Program Head, Respiratory Development Unit | Novartis KAY BOYCOTT | Chief Executive Officer | Asthma UK and British Lung Foundation
Patenting in a pandemic: How can you make your IP future-proof and flexible?
The world of healthcare has changed enormously in the last 12 months. Many companies aren’t letting a crisis go to waste – they are repurposing drugs to treat Covid-19 and rushing to protect potential IP. Others haven’t been so fortunate – lockdown has prevented them from generating the data needed to secure patents.
Building flexibility into your patent portfolio is more important now than ever. Through case studies, we will discuss:
Options for securing effective IP on repurposed drugs.
Tips for speeding up and slowing down prosecution.
Powers that Governments have to use patented drugs and the enforcement of IP rights for Covid vaccines and treatments.
Securing IP for Covid-related inventions: the balance between patenting for profit and philanthropy.
PANELLISTS INCLUDE
AMANDA SIMONS | Partner, Patent Attorney | J A Kemp LLP GRAHAM LEWIS | Partner, Patent Attorney | J A Kemp LLP
The rare disease area has seen a steady increase in awareness, and in the number of drugs being developed. In this panel, we will discuss the unique challenges in developing treatments for rare diseases, and how we can overcome them.
FACILITATED BY
RON JORTNER | Managing Director & Trustee | Masthead Biosciences & Cambridge Rare Disease Network
PANELLISTS INCLUDE
PATRICK SHORT | Co-founder and Chief Executive Officer | Sano Genetics VANESSA LEMARIE | Lead, Rare Disease Initiative | Ada Health STEVE ANDERSON | Chief Scientific Officer | Covance NICK SIREAU | Chair and Chief Executive Officer | AKU Society JOHN McDERMOTT | Executive Drug Development Consultant | Quotient Sciences
Covid-19 has meant rapid adoption of digital health across the system. As health and care become digital by default, what should pharma do next? Should they think internally, utilising digital health to improve their own processes; tactically, with digital health offerings for their own brands; or as a strategic partner, supporting health economies to be more sustainable, efficient and resilient? Join us as we discuss the changing landscape?
FACILITATED BY
HASSAN CHAUDHURY | Digital Health Lead | Department for International Trade
PANELLISTS INCLUDE
RACHEL MURPHY | Chief Executive Officer | Difrent MATTHEW CLEMENTE | Vice President, Device Development, Device R&D | Novo Nordisk STEFAN SUTER | Head Europe | Holmusk ANTHONY DAY | Blockchain Partner, Global Business Services | IBM HAKIM YADI | Co-Founder and Chief Executive | Closed Loop Medicine KONRAD DOBSCHUETZ | Head of Customer Solutions, (Digital) Health Innovation and BIOME Lead UK | Novartis
Are we making the most of data and digital technologies for pharma manufacturing?
FACILITATED BY
DAVE TUDOR | Managing Director, Medicines Manufacturing Innovation Centre | CPI
PANELLISTS INCLUDE
JASON LACOMBE | Chief Executive Officer | Veratrak ASHLEY HOWARD | EMEA Manager | APG Pharma Solutions | Applied Materials JON-PAUL SHERLOCK | Global Technology Strategy Director, MS&T | AstraZeneca ANDY DWYER | Ware Pilot Plant & Global Manufacturing Technology Director | GSK JOHANNES KHINAST | Head, Institute for Process and Particle Engineering & Scientific Director | Graz University of Technology & Research Centre Pharmaceutical Engineering
What are pharma companies looking for when it comes to new technologies; how do they find them, what are they trying to fix and how to go about accessing them
FACILITATED BY
MARK CASSIDY | Vice President of Global Business Strategy | Ajinomoto Bio-Pharma Services
PANELLISTS INCLUDE
JOE DE SOUSA | Senior Leader, Non-Exec Director and Independent Consultant | Melhor Consulting PAUL TUNNAH | Chief Content Officer & Managing Director UK | healthware MARK BUSWELL | Vice President, Vaccines Tech | GSK TIM LUKER | Vice President Emerging Technology and Innovation | Eli Lilly CRAIG GRANT | Global Director, Solid Form & Particle Engineering | Johnson Matthey
What is the role of technology in healthcare? How are tech giants and pharma companies collaborating to drive innovation in healthcare? Hear from some of the leaders in Pharma R&D and cutting-edge tech companies on how they see the future of innovation in healthcare.
JOHN TSAI | Head of Global Drug Development, Chief Medical Officer | Novartis SIR MENELAS (MENE) PANGALOS | Executive Vice President, BioPharmaceuticals R&D | AstraZeneca FRANCESCO DE RUBERTIS | Co-founder and Partner | Medicxi MIKE REA | Strategic Innovation Advisor and Chief Executive Officer | Nanoform and IDEA Pharma JESSICA MEGA | Chief Medical and Scientific Officer | Verily Life Sciences
Seeing is believing: Patient focussed manufacturing
The panel will address:
• Solutions by simulation • Reconfiguring patient healthcare through digital technology • Better patient outcomes, lower-cost healthcare, data-driven innovation
FACILITATED BY
JO PISANI | Strategic Advisor, Non-Executive Director and Charity Trustee
PANELLISTS INCLUDE
ROMA MAGUIRE | Professor of Digital Health and Care | University of Strathclyde JAGJIT SINGH SRAI | Head, Centre for International Manufacturing, Institute for Manufacturing | University of Cambridge GEORGE CROOKS | Chief Executive Officer | Digital Health & Care Institute PATRICK HYETT | Pharma Supply Chain Tech Digital Innovation Lead | GlaxoSmithKline STEPHEN TINDAL | (Consultant) Director, Science & Technology | Catalent Pharma Solutions
Partnership for innovation: how medicines will be made in future
We aspire to bring together the incredible talents of the pharma tech industry to bring forward the next generation of therapeutics – delivered in a cheaper and greener way.
It is now apparent that true collaboration holds the key to realising this aspiration. Science-led innovation on both sides of the fence is required to ensure access to the best experience, expertise and infrastructure wherever it resides. The ‘them and us’ outsourcing model of the past is being replaced, wherein innovation partnerships are being leveraged to produce much more efficient and effective drug discovery, development and supply.
Industry 4.0 and the digital transformation? New modalities? Big data? Shared risk and reward? Let’s properly re-imagine the future alliances essential to get new medicines to all those that need them across the globe.
FACILITATED BY
RICHARD WEAVER | Founder and Managing Director and Senior Vice President – Pre-clinical Development | XenoGesis and Sygnature Discovery
PANELLISTS INCLUDE
DAVID HARRISON | Senior Director External Manufacturing & Alliances | UCB ROSS BURN | Chief Executive Officer | CatSci and CDD ROB HARRIS | Director | Beyond Quality KATIE MURRAY | Technology Director Medicines Manufacturing Innovation Centre | CPI DETLEF BEHRENS | Managing Director | Bay Pharma ERIC DE VOS | VP of Global Innovation & Director of R&D Europe | Ajinomoto Bio-Pharma Services
The Power of Two – Making Strategic Partnerships Work
More than ever, our current situation has revealed the interdependency of pharma, CMOs and the supply chain. What’s the next evolution of strategic partnerships? How do organisational leaders create the right environment for true synergy and symbiosis? What role does technology play in forging stronger relationships and how can we creatively adapt current business models to work more collaboratively?
FACILITATED BY
STUART NEEDLEMAN | Chief Commercial Officer | Piramal Pharma Solutions
PANELLISTS INCLUDE
NATALIA NOVAC | Senior Director, Emerging Technology & Innovation, Corporate Business Development | Eli Lilly JULIETTE WHITE | Vice President, Global External Sourcing | AstraZeneca NICK JOHNSON | Chief Strategy Officer | Cell and Gene Therapy Catapult KAROLINA NIEWOLA | Business Development and Strategic Alliance Manager | iOnctura NEIL JONES | Director Business Development, EU | Catalent Pharma Solutions
Experiences of how we can lead our teams through change when it is imposed upon us
How challenge creates opportunities
How we can harness new ways of working to a more productive future
FACILITATED BY
KATHRYN SIMPSON | Business Consultant | Kathryn Simpson Consulting
PANELLISTS INCLUDE
PRIYA MANDE | Chief Operating Officer | PsiOxus Therapeutics SIMON HIRST | Chief Executive Officer | Sygnature Discovery EMMA SCEATS | Chief Executive | Isogenica MICHELE LESUEUR | Hematology Oncology Business Unit Director | Celgene KIMBERLY SMITH | Head of Global Research and Medical Strategy | ViiV Healthcare
The pharma and lifesciences ecosystem was already facing significant opportunities and disruption from technology advances, pricing pressure, digital and new entrants. In a Covid-19 world and with Brexit uncertainty the level of disruption has only been amplified. This panel will explore the disruptive themes and key success factors for companies to navigate our changing environment.
FACILITATED BY
JO PISANI | Strategic Advisor, Non Executive Director and Charity Trustee
PANELLISTS INCLUDE
JOHN DAWSON | Chief Executive Officer | Oxford Biomedica RICHARD TORBETT | Chief Executive Officer | ABPI BRIAN HENRY | Vice President, Global Head of Drug Product Design | Pfizer Worldwide Research and Development GLENN CROCKER | Head of Life Sciences, JLL & Chairman, BioCity Group | JLL & BioCity Group NICOLE MATHER | Executive Partner, Life Sciences Lead | IBM Services
